Press coverage about Argos Therapeutics (NASDAQ:ARGS) has trended somewhat positive recently, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Argos Therapeutics earned a news sentiment score of 0.04 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.1089570541987 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:
- Argos Therapeutics, Inc. (ARGS) is at $0.15 per share and Masimo Corporation (MASI) is listed at $86.84 – Stocks Gallery (stocksgallery.com)
- Contrasting Argos Therapeutics (ARGS) & Its Rivals (americanbankingnews.com)
- Stock’s Technical Analysis – Argos Therapeutics, Inc., (NASDAQ: ARGS) – Stock Watch (stocksnewstimes.com)
- Argos Therapeutics, Inc. (ARGS) Short Interest Down 21.1% in October (americanbankingnews.com)
- Argos Therapeutics (ARGS) & Its Competitors Head to Head Comparison (americanbankingnews.com)
Argos Therapeutics (NASDAQ:ARGS) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.10 million. Argos Therapeutics had a negative net margin of 12,391.15% and a negative return on equity of 1,532.49%.
Separately, Zacks Investment Research lowered shares of Argos Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, August 14th. One equities research analyst has rated the stock with a sell rating and three have given a hold rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $4.13.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.